Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice

21 Feb 2017

Abstract excerpt

Expression of PD-L1, the ligand for T-cell inhibitory receptor PD-1, is one key immunosuppressive mechanism by which cancer avoids eradication by the immune system. Therapeutic use of blocking antibodies to PD-L1 or its receptor PD-1 has produced unparalleled, durable clinical responses, with highest likelihood of response seen in patients whose tumour or immune cells express PD-L1 before therapy. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immune Cell Function and Interaction

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 28220772
DOI: 10.1038/ncomms14572

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in micePMID 28220772Read ↗

Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape.Semantic proximity Read ↗

Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to TherapySemantic proximity Read ↗

Regulatory mechanisms of PD-1/PD-L1 in cancersSemantic proximity Read ↗

A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies.Semantic proximity Read ↗

Cellular mechanisms of combining innate immunity activation with PD-1/PD-L1 blockade in treatment of colorectal cancerSemantic proximity Read ↗

Immune surveillance of tumorsSemantic proximity Read ↗

PD-1/PD-L1 axis: implications in immune regulation, cancer progression, and translational applicationsSemantic proximity Read ↗

Clinical implications of tumor-intrinsic mechanisms regulating PD-L1Semantic proximity Read ↗

PD-L1: expression regulationSemantic proximity Read ↗

Recent Findings in the Regulation of Programmed Death Ligand 1 ExpressionSemantic proximity Read ↗

Lymphatic PD-L1 expression restricts tumor-specific CD8 <sup>+</sup> T cell responsesSemantic proximity Read ↗

Targeting PD-L1 in solid cancer with myeloid cells expressing a CAR-like immune receptorSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.